RE:RE:RE:RE:RE:RE:RE:Determining a Company’s Value - Old Schoolfredgoodwinson wrote: Yes GBM has gone Rumpl being twice excluded in the Presentation of the 7th of Feb. and indeterminate delays to NSCLC.
Big Pharma must be in seventh heaven.
In the meantime something on Covid 19 might give them the $$$ boost they need. They really do need to partner with someone on other indications, that has always been their plan, Covid didn't just push back TLT, but any potential partners on other Indications. GBM, although promising for TLT and great headlines, is a very rare cancer and not a huge $$$ maker. NSCLC, I'd be surprised if that, or Breast, isn't first Solid tumor indication they aim their ACT at. TLT's ACT hasn't gone anywhere, it is right there at LKSTI... I'm in this one for the long haul Fred, and you?